<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 09 Apr 2021 19:19:38 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>首个伊布替尼仿制药申报上市！原研2020年销售额94亿美元</title><link>https://mp.weixin.qq.com/s/OxcsbuLuaDjng-YdsRpZiw</link><description></description><content:encoded><![CDATA[首个伊布替尼仿制药申报上市！原研2020年销售额94亿美元]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>基石药业「普拉替尼胶囊」新适应症上市申请拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/ZyUAitOlkN4x0NB6RIWetA</link><description></description><content:encoded><![CDATA[基石药业「普拉替尼胶囊」新适应症上市申请拟纳入优先审评]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>国内企业首家——朗来科技P2X3受体选择性拮抗剂临床申请正式受理</title><link>https://mp.weixin.qq.com/s/WXJv3URhHH-lGeKkoQ8MMw</link><description></description><content:encoded><![CDATA[国内企业首家——朗来科技P2X3受体选择性拮抗剂临床申请正式受理]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>国内首个CD70抗体药物申报临床</title><link>https://mp.weixin.qq.com/s/ssLOz2ZTx-GjgvVvSlw7pw</link><description></description><content:encoded><![CDATA[国内首个CD70抗体药物申报临床]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>新疆牵头省际集采来袭，10品种开启报量</title><link>https://mp.weixin.qq.com/s/4itXT2g1Y-H_ZbOd_w56bg</link><description></description><content:encoded><![CDATA[新疆牵头省际集采来袭，10品种开启报量]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>Opdivo联合疗法治疗食管鳞癌III期研究成功</title><link>https://mp.weixin.qq.com/s/QHmN9pNZIC7pFaHcApdB-w</link><description></description><content:encoded><![CDATA[Opdivo联合疗法治疗食管鳞癌III期研究成功]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>Keytruda单药辅助治疗肾细胞癌III期研究成功</title><link>https://mp.weixin.qq.com/s/0Gpc2fdJp5npGSqwcQGqbA</link><description></description><content:encoded><![CDATA[Keytruda单药辅助治疗肾细胞癌III期研究成功]]></content:encoded><pubDate>Fri, 09 Apr 2021 17:39:41 +0800</pubDate></item><item><title>NSCLC术后辅助治疗！奥希替尼新适应症获批</title><link>https://mp.weixin.qq.com/s/MA5-GP-bgO9BYB_7Q27Ztw</link><description></description><content:encoded><![CDATA[NSCLC术后辅助治疗！奥希替尼新适应症获批]]></content:encoded><pubDate>Thu, 08 Apr 2021 09:31:00 +0800</pubDate></item><item><title>特瑞普利单抗第3项适应症获批！治疗尿路上皮癌</title><link>https://mp.weixin.qq.com/s/RZe7xABa2E8REctuH6ir-Q</link><description></description><content:encoded><![CDATA[特瑞普利单抗第3项适应症获批！治疗尿路上皮癌]]></content:encoded><pubDate>Thu, 08 Apr 2021 09:31:00 +0800</pubDate></item><item><title>武田「醋酸艾替班特注射液」在华获批上市</title><link>https://mp.weixin.qq.com/s/BR7EQbxNWTJxpAuLY_jnIQ</link><description></description><content:encoded><![CDATA[武田「醋酸艾替班特注射液」在华获批上市]]></content:encoded><pubDate>Thu, 08 Apr 2021 09:31:00 +0800</pubDate></item><item><title>国内首个申报上市PI3K抑制剂拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/8iAL7qBI4OSLWIVXuE_o6w</link><description></description><content:encoded><![CDATA[国内首个申报上市PI3K抑制剂拟纳入优先审评]]></content:encoded><pubDate>Wed, 07 Apr 2021 17:37:03 +0800</pubDate></item><item><title>首个GLP-1/FGF21双重激动剂同时获批2项临床</title><link>https://mp.weixin.qq.com/s/ZlqoQOw7QLwR-4-AdZzrFg</link><description></description><content:encoded><![CDATA[首个GLP-1/FGF21双重激动剂同时获批2项临床]]></content:encoded><pubDate>Wed, 07 Apr 2021 17:37:03 +0800</pubDate></item><item><title>君实生物CTLA-4 单抗临床申请获受理</title><link>https://mp.weixin.qq.com/s/BQoCo6TEKL7uTkdTsuK5HA</link><description></description><content:encoded><![CDATA[君实生物CTLA-4 单抗临床申请获受理]]></content:encoded><pubDate>Wed, 07 Apr 2021 17:37:03 +0800</pubDate></item><item><title>全球首个BTK-PROTAC获批临床</title><link>https://mp.weixin.qq.com/s/X6mDycMtjo2kNXxphdwxqA</link><description></description><content:encoded><![CDATA[全球首个BTK-PROTAC获批临床]]></content:encoded><pubDate>Tue, 06 Apr 2021 18:24:56 +0800</pubDate></item><item><title>2021年3月 | 失败临床研究TOP10</title><link>https://mp.weixin.qq.com/s/5RasJHathbj9Y8RE9ZDGdw</link><description></description><content:encoded><![CDATA[2021年3月 | 失败临床研究TOP10]]></content:encoded><pubDate>Tue, 06 Apr 2021 18:24:56 +0800</pubDate></item><item><title>近十年来首个非兴奋剂类ADHD药物获FDA批准上市</title><link>https://mp.weixin.qq.com/s/hRWQtuSfMi-6bl1cdWkTsg</link><description></description><content:encoded><![CDATA[近十年来首个非兴奋剂类ADHD药物获FDA批准上市]]></content:encoded><pubDate>Tue, 06 Apr 2021 18:24:56 +0800</pubDate></item><item><title>贝达药业KRAS G12C抑制剂获批临床</title><link>https://mp.weixin.qq.com/s/IVSuwX5w8DtpjeiioYugtA</link><description></description><content:encoded><![CDATA[贝达药业KRAS G12C抑制剂获批临床]]></content:encoded><pubDate>Tue, 06 Apr 2021 18:24:56 +0800</pubDate></item><item><title>强生/传奇生物BCMA CAR-T完成美国BLA滚动申请</title><link>https://mp.weixin.qq.com/s/WanAYGzgj3lMZOYFcqxFrQ</link><description></description><content:encoded><![CDATA[强生/传奇生物BCMA CAR-T完成美国BLA滚动申请]]></content:encoded><pubDate>Tue, 06 Apr 2021 18:24:56 +0800</pubDate></item><item><title>上市还有希望吗？渤健阿尔茨海默症单抗aducanumab再遭FDA委员会抨击</title><link>https://mp.weixin.qq.com/s/NByZLuz16MOpj_ZB1S8bCg</link><description></description><content:encoded><![CDATA[上市还有希望吗？渤健阿尔茨海默症单抗aducanumab再遭FDA委员会抨击]]></content:encoded><pubDate>Fri, 02 Apr 2021 18:30:20 +0800</pubDate></item><item><title>京津冀晋11品种集采4月15日开标，中标规则对标国采</title><link>https://mp.weixin.qq.com/s/vRavNIscoek4VuQqq_bwZg</link><description></description><content:encoded><![CDATA[京津冀晋11品种集采4月15日开标，中标规则对标国采]]></content:encoded><pubDate>Fri, 02 Apr 2021 18:30:20 +0800</pubDate></item></channel></rss>